Human immunodeficiency virus infection due to clotting factor concentrates: results of the Seroconversion Surveillance Project.
From 1987 to the present, the Seroconversion Surveillance Project has provided the means by which to monitor the risk of transmission of human immunodeficiency virus (HIV) by clotting factor concentrates. One hundred thirty-one hemophilia treatment centers in the United States are contacted regularly, and data on HIV testing of patients are collected. To date, 4366 (46.0%) of 9496 patients have been reported to be seropositive, and 37 new seroconversions have been identified. Nine of these have met the Centers for Disease Control criteria for seroconversion while the patient was taking factor concentrate. None of the nine seroconversions were due to concentrates that had been treated to inactivate viruses and made from plasma that had been tested for HIV antibody. These results indicate that there is a high prevalence of seropositivity in affected patient groups, but that the risk of HIV infection from currently available clotting factor concentrates is extremely low.
Fricke
W
W
Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland.
Augustyniak
L
L
Lawrence
D
D
Brownstein
A
A
Kramer
A
A
Evatt
B
B
D001778:Blood Coagulation Disorders / Q000097:blood; D001779:Blood Coagulation Factors / Q000009:adverse effects*; D015658:HIV Infections / Q000635:transmission*; D006679:HIV Seropositivity / Q000382:microbiology; D006467:Hemophilia A / Q000097:blood; D006801:Humans
D001779:Blood Coagulation Factors